CN1915401B - Composition of Chinese traditional medicine for treating phthisis, and application - Google Patents
Composition of Chinese traditional medicine for treating phthisis, and application Download PDFInfo
- Publication number
- CN1915401B CN1915401B CN2006100522399A CN200610052239A CN1915401B CN 1915401 B CN1915401 B CN 1915401B CN 2006100522399 A CN2006100522399 A CN 2006100522399A CN 200610052239 A CN200610052239 A CN 200610052239A CN 1915401 B CN1915401 B CN 1915401B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- treatment
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 41
- 208000008128 pulmonary tuberculosis Diseases 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title claims description 15
- 239000000463 material Substances 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 9
- 239000000654 additive Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000006188 syrup Substances 0.000 claims description 6
- 235000020357 syrup Nutrition 0.000 claims description 6
- 241000545442 Radix Species 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 4
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 4
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 claims description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 238000012869 ethanol precipitation Methods 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 3
- 241001313855 Bletilla Species 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 241001671204 Stemona Species 0.000 abstract 1
- 241000245665 Taraxacum Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 16
- 229940079593 drug Drugs 0.000 description 11
- 201000008827 tuberculosis Diseases 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 239000003172 expectorant agent Substances 0.000 description 7
- 230000003419 expectorant effect Effects 0.000 description 7
- 206010059866 Drug resistance Diseases 0.000 description 6
- 241000193830 Bacillus <bacterium> Species 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001355 anti-mycobacterial effect Effects 0.000 description 1
- 239000003926 antimycobacterial agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005206 pyrazinamide Drugs 0.000 description 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A Chinese medicine in the form of particle or others for treating pulmonary tuberculosis is prepared from 6 Chinese-medicinal materials including dandelion herb, fleece flower root, stemona root, bletilla tuber, etc. Its preparing process is also disclosed.
Description
Technical field
The present invention relates to Chinese patent medicine, specifically a kind of is the Chinese medicine composition and the application thereof of the treatment pulmonary tuberculosis of main component with Chinese medicine.
Background technology
Pulmonary tuberculosis is a kind of common difficult and complicated illness, is a kind of more common chronic infectious disease that is caused by mycobacterium tuberculosis infection.Tuberculosis all can take place in the various tissues of human body and each organ, but the most common with lungs, the tuberculosis that betides pulmonary then is called pulmonary tuberculosis.Treat general clinical use Western medicine of pulmonary tuberculosis and chemotherapy both at home and abroad.The phthisical Western medicine of modern clinical treatment mainly contains isoniazid: its main side effects is easy excitement, insomnia, refreshing directly scorching, the even liver function injury that has of tip; Rifampicin: its main side effects is liver function injury, thrombocytopenia, the easy teratogenesis tire of pregnant early stage women; Pyrazinamide: its main side effects is gastrointestinal reaction, liver function injury, arthralgia; Ethambutol: its main side effects is a visual deterioration.More than several Western medicine generally all be used in combination during pulmonary tuberculosis in treatment, though certain therapeutic effect is also arranged, its toxic and side effects can bring new disease with painful to the patient.Chemotherapy can make the state of an illness alleviate to a certain extent, just control energy discharge of bacteria 95-100%, the expectorant bacterium obtains cloudy the commentaries on classics, but chemotherapy all has certain side effect to patient's liver, kidney, gastrointestinal function, cause many patients can not adhere to medication, long-term irregular taking medicine, tubercule bacillus produces drug resistance, the drug resistance case increases and pathological changes remains unchanged for a long period of time thereby make, so caused very big misery to the patient. because variation of tuberculosis bacterial strain and drug resistance increase day by day.The effect that causes original antimycobacterial drug is obviously not as the past, and the antitubercular agent that some curative effects are preferable such as Rimactazid, streptomycin etc. obviously descend to the tubercule bacillus sensitivity, and bigger toxic and side effects is arranged; Patient is difficult to accept secular chemotherapy again, so cause that pulmonary tuberculosis is quietly grown again, surging moisture regain, is threatening human beings'health once more.At present, China's pulmonary tuberculosis patient has 4,500,000, wherein, and infectiousness pulmonary tuberculosis patient about 1,500,000.1,450,000 new cases are arranged every year approximately, and annual number because of tuberculosis death reaches 130,000.The tuberculosis number of China occupies second in the whole world, and 80% pulmonary tuberculosis patient is in the rural area.China is classified as the tuberculosis drug resistance by World Health Organization (WHO) and is subjected to one of countries and regions of special caution.Moreover pulmonary tuberculosis is the source of other position tuberculosis of health and various complication often, and it has become the difficult problem of a treatment again in today.At above variety of issue, the present invention has developed a kind of pure Chinese medicinal preparation that has advantages such as good effect, the cycle is short, price is low, have no side effect aspect the pulmonary tuberculosis in treatment for this reason.This also is a major issue that promotes the well-being of mankind
Summary of the invention
Purpose of the present invention is exactly in order to address the above problem, and providing a kind of is that having of main component suppressed and the removing tubercule bacillus with Chinese medicine, and pulmonary's tuberculous foci is disappeared; Improve and the adjustment immunity of organism; To treatment pulmonary tuberculosis obvious results preparation of drug combination method and application.
At the deficiencies in the prior art, the invention allows for and a kind ofly have in treatment that good effect, cycle are lacked, had no side effect, the pharmaceutical composition of advantage such as cheap, pollution-free aspect the pulmonary tuberculosis.
The consumption of drug component of the present invention is groped to sum up to draw through the inventor in a large number, and each amounts of components all has curative effect preferably in following ranges, and medicine of the present invention contains
166～498 parts of 166～498 portions of Pseudobulbus Bletillae (Rhizoma Bletillae)s of 331～999 parts of Herba Taraxacis of Herba humuli scandentis
110～330 parts of 166～498 parts of Radixs Stemonae of 166～498 parts of Radix Polygoni Multiflori of Rhizoma Polygonati
Preferable range is:
248～496 parts of 248～496 portions of Pseudobulbus Bletillae (Rhizoma Bletillae)s of 498～998 parts of Herba Taraxacis of Herba humuli scandentis
165～275 parts of 248～496 parts of Radixs Stemonae of 248～496 parts of Radix Polygoni Multiflori of Rhizoma Polygonati
The best is:
331 parts of 331 portions of Pseudobulbus Bletillae (Rhizoma Bletillae)s of 662 parts of Herba Taraxacis of Herba humuli scandentis
220 parts of 331 parts of Radixs Stemonae of 331 parts of Radix Polygoni Multiflori of Rhizoma Polygonati
Technical problem to be solved by this invention is to realize by following technical scheme.Be characterized in that with Herba humuli scandentis, Herba Taraxaci, Rhizoma Polygonati, Radix Polygoni Multiflori etc. be the medicine that raw material is made.The phthisical pharmaceutical composition of this treatment is characterized in that it is that component is formed or made active component and pharmaceutically acceptable additives are formed or make active component and pharmaceutically acceptable additives are formed by the alcohol extract of following main materials by the water extract of following main materials by following main materials.
Medicine of the present invention can adopt the Chinese medicine preparation conventional method to be prepared into any pharmaceutically useful conventional formulation.For example these crude drug pulverize mix homogeneously can be made powder takes after mixing it with water; Also can be with these medicines decocting together, the condensed water decocting liquid is made oral liquid then; But, preferably crude drug Herba humuli scandentis, Herba Taraxaci, Radix Polygoni Multiflori are carried out special extraction such as ethanol extraction, but this can not limit protection scope of the present invention in order to make each crude drug of this medicine better bring into play drug effect.
Described pharmaceutically acceptable additives are following one or more: citric acid, sodium bicarbonate, ethyl hydroxybenzoate, tartaric acid, lecithin, sodium lauryl sulphate, glycerol, gelatin, Polyethylene Glycol, glycerol monolaurate (gelucire44/14), propylene glycol, dextrin, ethanol, dried starch.
Its dosage form can be a said dosage form on any pharmaceutics, as syrup, granule, capsule, tablet etc.; Described capsule can be common capsule, effervescent capsule or other various suitable capsules; Described tablet can be common tablet, effervescent tablet, dispersible tablet or other various suitable tablets, can be with suitable coating material coating also coating not; Preferred syrup.
The specific embodiment
Describe implementation of the present invention in detail below in conjunction with embodiment.
Embodiment 1:
The preparation method of syrup of the present invention:
Take by weighing each raw material: Herba humuli scandentis 450 grams, Herba Taraxaci 450 grams, Radix Polygoni Multiflori 400 grams, the Radix Stemonae 400 grams, the Pseudobulbus Bletillae (Rhizoma Bletillae) 250 grams, Rhizoma Polygonati 250 gram decocting secondaries each 1 hour, filter, merging filtrate, be condensed into thick paste, add the ethanol precipitation secondary, make to contain pure flow control and once reach 65%, for the second time reach 80%, filter, reclaim ethanol and be concentrated into about 700mL, stir molten with sucrose, ethyl hydroxybenzoate alcohol liquid while hot, add boiling water again to full dose, stir evenly promptly.
Embodiment 2:
The preparation method of dissolved granule of the present invention:
Take by weighing Herba humuli scandentis 500 grams, Herba Taraxaci 050 gram, Radix Polygoni Multiflori 500 grams, the Radix Stemonae 300 grams, the Pseudobulbus Bletillae (Rhizoma Bletillae) 3000 grams, Rhizoma Polygonati 300 grams.Said medicine pulverized grinds into coarser powder, the decocting secondary, 2 hours for the first time, 1 hour for the second time, filter, filtrate is condensed into thick paste, drying was pulverized 100 mesh sieves, mixing, moistening, soften, take out when forming agglomerate, make dissolved granule.
Embodiment 3:
(a) ethanol with Herba humuli scandentis, Herba Taraxaci, Radix Polygoni Multiflori 70%～95% with described weight proportion carries out reflux, extract, twice, merges extracted twice liquid, reclaims ethanol, and is dry under 45～55 ℃, gets dry extract 1;
(b) residue after Rhizoma Polygonati, the Pseudobulbus Bletillae (Rhizoma Bletillae), the Radix Stemonae and the Herba humuli scandentis of described weight proportion, Herba Taraxaci, the Radix Polygoni Multiflori alcohol extraction is decocted with water twice, add water serves as easy not have powder at every turn, merge decocting liquid twice, filter to get filtrate 2, it is 1.15～1.35 extractum that concentrated filtrate becomes proportion, dry under 45～55 ℃, get dry extract 2;
(c) merge dry extract 1 and 2, it is ground into powder, the active component of preparation cost invention medicine;
(d) with gained active component and pharmaceutically acceptable additives such as correctives, the abundant mixing of adjuvant, make any dosage form of pharmaceutics.As above-mentioned active component was pulverized 100 mesh sieves, with pharmaceutically acceptable additives such as mixings such as ethanol, starch, moistening, soften, take out when forming agglomerate, can be made into tablet after making granule and suitable additives mixing.
In the above-mentioned preparation method, when in the preferred steps (a) medicine being added ethanol extraction, adding amount of alcohol for the first time is 12 times, extracts 1 hour, and add amount of alcohol the second time is 10 times, extracts 1 hour.(b) during with the medicine extracting in water, add 10 times in water for the first time in, decocted 2 hours, add 8 times in water the second time, decocted 1.5 hours.
In like manner, press the method for embodiment 3, add suitable attached capsule etc.
Preparation tool aromatic odor of the present invention, mildly bitter flavor acid, nontoxic, sepia syrup, faint yellow granule or tablet or capsule are arranged.
More than during each forms, weight is calculated with crude drug, in the present invention, if weight is unit with the gram, this composition can be made into 1000 doses of pharmaceutical preparatioies, described 1000 doses of fingers, 1000 doses in the final drug preparation of making, as make 1000 in 1000 of capsule preparations, 1000 in tablet, granule 1000g, oral liquid 1000 peace bottles, injection 1000 peace bottles, drop pill etc., also can make big packing as granule, as 100-500 bags, specifically can be 100 bags, 150 bags, 200 bags, 250 bags, 500 bags, every bag can be used as dose 1 time.This weight of formulation can increase or reduce, but the raw medicinal herbs weight proportion constant rate between each composition.
The present invention be at distinguished veteran doctors of TCM on the basis of proved recipe, through a large amount of preparation technology test and the resulting pure Chinese medicinal preparation of clinical practice.Treating both the principal and secondary aspects of a disease of the present invention, evident in efficacy, have nourishing YIN and clearing away heat, the sterilization of anti-consumptive disease, the merit only of eliminating the phlegm, can give full play to and kill tubercule bacillus, improve the effect of various symptoms of pulmonary tuberculosis and promotion physical rehabilitation.
Advantage of the present invention is to compare with similar Western medicine, it has reasonable recipe, drug resistance evident in efficacy, no and Drug resistance, has no side effect, treatment cycle is short, and low price the patient easily accept, taking convenience, mouthfeel be good, suitable advantage such as takes for a long time, is a kind of pure Chinese medicinal preparation that is used for the treatment of pulmonary tuberculosis.
For a better understanding of the present invention, below further set forth medicine of the present invention at clinical action effect, but not to the restriction of effect of the present invention.
Concrete clinical practice is as follows:
1. clinical subjects: male 326 examples in the treatment group of the present invention, women 66 examples.The course of disease 1～3 year.The general use 3 courses of treatment of medicine of the present invention, 3 months each courses of treatment.Other matched group situation sees the following form.
2. clinical trial:
Phthisical comprehensive therapeutic effect standard is as follows:
Clinical cure.Pulmonary lesion does not have activeness, and the cavity is closed, and expectorant bacterium continuously negative (looking into expectorant at least in every month 1 time) all reaches more than 6 months.Still exist as the cavity, then must the expectorant bacterium negative continuously more than 1 year.
Significantly effectively.The expectorant bacterium is continuously cloudy to be changeed, and pathological changes obviously absorbs or absorbs, and cavity closure or dwindle all reaches person more than 3 months.
Effectively.Sputum conversion, pathological changes obviously absorb, absorb or do not have a change; The cavity is closed, dwindles or does not have change, all reaches more than 1 month.The expectorant bacterium is cloudy continuously to be changeed, and pathological changes absorbs, and the cavity dwindles, and all reaches more than 1 month.
Invalid.Expectorant bacterium and X line all do not have the changer.
Clinical test results sees the following form:
Characteristics of the present invention are:
1. be the All Pure Nature pharmaceutical preparation, do not have strict indication and toxic and side effect;
2. the employing peroral dosage form is easy to use, and mouthfeel is good, and the patient easily accepts;
3. suppress and remove tubercle bacillus to act on by force, medication 9 months, sputum negative conversion rate can reach more than 55.86%;
Total effective rate is up to 98.47%;
4. medical expense is low, but than the conventional therapy cost saving more than 50%;
5. be easy to apply.
Claims (7)
1. treat phthisical Chinese medicine composition for one kind, it is characterized in that: it is by the water extract of following raw materials according or alcohol extract is made active component and pharmaceutically receptible additives are formed, and the weight portion of each raw material is: 165～275 parts of 248～496 parts of Radixs Stemonae of 248～496 parts of Radix Polygoni Multiflori of 248～496 parts of Rhizoma Polygonatis of 248～496 portions of Pseudobulbus Bletillae (Rhizoma Bletillae)s of 498～998 parts of Herba Taraxacis of Herba humuli scandentis.
2. a kind of Chinese medicine composition for the treatment of pulmonary tuberculosis according to claim 1, it is characterized in that: the weight portion of described each raw material is: 220 parts of 331 parts of Radixs Stemonae of 331 parts of Radix Polygoni Multiflori of 331 parts of Rhizoma Polygonatis of 331 portions of Pseudobulbus Bletillae (Rhizoma Bletillae)s of 662 parts of Herba Taraxacis of Herba humuli scandentis.
3. a kind of preparation method for the treatment of the Chinese medicine composition of pulmonary tuberculosis as claimed in claim 1, it is characterized in that comprising the steps: taking by weighing by weight each raw material, coarser powder is ground in the said medicine pulverizing, the decocting secondary, each 1 hour, filter, merging filtrate is condensed into thick paste, add the ethanol precipitation secondary, make to contain pure flow control and once reach 65%, reach 80% for the second time, filter, reclaim ethanol and be concentrated into 700mL, stir moltenly while hot with sucrose, ethyl hydroxybenzoate alcohol liquid, add boiling water again, stir evenly and make syrup to full dose.
5. a kind of Chinese medicine composition for the treatment of pulmonary tuberculosis according to claim 1 is characterized in that: described pharmaceutically receptible additives are following more than one: citric acid, sodium bicarbonate, ethyl hydroxybenzoate, tartaric acid, lecithin, sodium lauryl sulphate, glycerol, gelatin, Polyethylene Glycol, glycerol monolaurate, propylene glycol, dextrin, ethanol and dried starch.
6. the phthisical Chinese medicine composition of a kind of treatment according to claim 1, it is characterized in that: its dosage form is syrup, granule, capsule or tablet.
7. the phthisical Chinese medicine composition of a kind of treatment according to claim 6, it is characterized in that: described capsule is the effervescent capsule.
8. the phthisical Chinese medicine composition of a kind of treatment according to claim 6 is characterized in that: described tablet is effervescent tablet or is dispersible tablet, with suitable coating material coating.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100522399A CN1915401B (en) | 2006-06-30 | 2006-06-30 | Composition of Chinese traditional medicine for treating phthisis, and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100522399A CN1915401B (en) | 2006-06-30 | 2006-06-30 | Composition of Chinese traditional medicine for treating phthisis, and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1915401A CN1915401A (en) | 2007-02-21 |
| CN1915401B true CN1915401B (en) | 2010-12-22 |
Family
ID=37736563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006100522399A Active CN1915401B (en) | 2006-06-30 | 2006-06-30 | Composition of Chinese traditional medicine for treating phthisis, and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1915401B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113018379A (en) * | 2021-03-24 | 2021-06-25 | 重庆智惠中医药研究院（普通合伙） | Traditional Chinese medicine compound for treating pulmonary tuberculosis and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1140601A (en) * | 1996-02-28 | 1997-01-22 | 杨树亮 | Traditional-Chinese-medicines antiphthitic preparation |
| CN1308956A (en) * | 2000-12-29 | 2001-08-22 | 武邵 | Capsule for treating pulmonary tuberculosis |
-
2006
- 2006-06-30 CN CN2006100522399A patent/CN1915401B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1140601A (en) * | 1996-02-28 | 1997-01-22 | 杨树亮 | Traditional-Chinese-medicines antiphthitic preparation |
| CN1308956A (en) * | 2000-12-29 | 2001-08-22 | 武邵 | Capsule for treating pulmonary tuberculosis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1915401A (en) | 2007-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105535439A (en) | Traditional Chinese medicinal composition for treating pharyngitis and preparation method thereof | |
| CN1935194B (en) | Preparation method of Chinese medicine composition for treating nephroma | |
| CN101011562B (en) | Novel formulation of shenqiwendan decoction and production method thereof | |
| JP2002154979A (en) | Medicine composition for i type allergy and method for producing the same | |
| CN101347605B (en) | Chinese medicinal composition for treating gout and preparation method and application thereof | |
| CN1814176B (en) | Chinese medicinal composition for treating tuberculosis and its preparation method | |
| CN1814195B (en) | Chinese medicine composition for treating gynecopathy and its preparation method thereof | |
| CN103830674A (en) | Medicament composition for treating lipomyoma and preparation method and application thereof | |
| CN101933973A (en) | Medicament composition for preventing and treating liver damage | |
| CN107890528B (en) | Traditional Chinese medicine composition for treating hyperuricemia and preparation method thereof | |
| CN103705578B (en) | There is blood fat reducing and Chinese medicine preparation suppressing blood glucose rising effect and preparation method thereof | |
| CN101850065B (en) | Chinese medicinal composition for treating gout | |
| CN1915401B (en) | Composition of Chinese traditional medicine for treating phthisis, and application | |
| CN101837093B (en) | Chinese medicinal composition for curing gout | |
| CN111358906B (en) | Traditional Chinese medicine composition suitable for exogenous diseases | |
| CN1830482B (en) | Chinese medicinal composition and application for treating child pneumonia for treating | |
| CN103181972A (en) | Tablet or capsule of traditional Chinese medicine for treating wind-heat type common cold and upper respiratory infection, and preparation method thereof | |
| CN1814250B (en) | Chinese medicine composition for treating liver cirrhosis ascites and preparation method thereof | |
| CN101278982A (en) | Chinese medicine compound preparation for curing acute or chronic hepatitis B and method of preparing the same | |
| CN1899425B (en) | Chinese medicine composition for treating emmeniopathy | |
| CN1814193B (en) | Chinese medicine composition for treating nephritis dropsy and preparation method thereof | |
| CN101700323B (en) | Pharmaceutical composition for preventing and treating liver cancer | |
| CN101085185A (en) | Beverage containing white peony root and gardenia | |
| CN100339093C (en) | Compound medicine for treating coronary heart disease and angina pectoris and its preparing process | |
| CN110711218A (en) | Traditional Chinese medicine composition for treating throat pain and cough |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20090109 Address after: Zhejiang city of Ningbo province Yinzhou District Yinxian Avenue East Zhejiang Pharmaceutical College No. 888 post encoding: 315100 Applicant after: Yang Xiong Zhi Co-applicant after: Yang Yijie Address before: 21, 4 floor, 293 South Rainbow Road, Jiangdong District, Zhejiang, Ningbo, China: 315040 Applicant before: Yang Yijie |
|
| ASS | Succession or assignment of patent right |
Owner name: YANG XIONGZHI Free format text: FORMER OWNER: YANG YIKAI Effective date: 20090109 |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: YANG YIKAI Effective date: 20130701 Owner name: SHENYANG HONGQI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: YANG XIONGZHI Effective date: 20130701 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 315100 NINGBO, ZHEJIANG PROVINCE TO: 110179 SHENYANG, LIAONING PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130701 Address after: Hunnan New Network street Shenyang city Liaoning province 110179 No. 6 Patentee after: Shenyang Hongqi Pharmaceutical Co., Ltd. Address before: 315100 Zhejiang city of Ningbo province Yinzhou District County Road No. 888 east section of Zhejiang Pharmaceutical College Patentee before: Yang Xiongzhi Patentee before: Yang Yijie |